TSRL is pleased to welcome Jessica Reed, PhD, as a Senior Scientific Advisor, adding more than 25 years of pharmaceutical discovery and development experience to the scientific leadership available to TSRL clients. An accomplished pharmaceutical executive and organic chemist, Dr. Reed has supported programs across the development lifecycle, including over 10 Investigational New Drug applications and 7 NDA/sNDA submissions. At TSRL, she provides scientific leadership and consulting support across nonclinical and clinical projects with a focus on strategic guidance, regulatory insight, and effective project execution.
“Jessica understands what it takes to move an idea through development and toward meaningful regulatory milestones,” said Dr. Elke Lipka, President and CEO of TSRL. “She brings the scientific depth to challenge assumptions, the development experience to anticipate what comes next, and the leadership skills to help multidisciplinary teams make smart decisions. That perspective is incredibly valuable to the programs we support.”
Throughout her career, Dr. Reed has contributed to the advancement of five clinical candidates, including dacomitinib, marketed as Vizimpro, an approved treatment for non-small cell lung cancer. Her therapeutic experience spans oncology, central nervous system disorders, cardiovascular and metabolic diseases. She has led cross-functional teams across early discovery and clinical development through roles at Pfizer, the Sarcoma Alliance for Research Through Collaboration (SARC), MMS holdings, Millendo Therapeutics, and other organizations.
Dr. Reed currently serves as CEO and Board Member of Diapin Therapeutics and Vice President of Development at GeneToBe, Inc. Her experience leading emerging biotechnology companies also gives her first hand understanding of the scientific, financial, and strategic decisions facing early-stage drug developers.
“Early drug development requires you to constantly connect the science in front of you with the decisions that will come later,” said Dr. Reed. “I’m excited to work with TSRL and help teams think strategically about their programs, identify potential challenges early, and build development paths grounded in strong science.”
Dr. Reed earned her PhD in Organic Chemistry from the University of Leeds. Throughout her career, she has also remained committed to mentoring scientists and building multidisciplinary teams capable of moving complex programs forward.
Her addition strengthens TSRL’s model of providing clients with direct access to experienced scientific leaders who have navigated drug development firsthand. This senior-level perspective helps TSRL serve as a development partner that can support both the immediate scientific challenge and the larger path toward the clinic.
For more information about TSRL and its scientific leadership, visit: https://www.tsrlinc.com/leadership.